Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor

Clinical Breast Cancer

Volumn 15, Issue 1, 2015, Pages e77-e81

  Sheu, Johanna ^a   Hawryluk, Elena B ^b   Litsas, Georgia ^c   Thakuria, Manisha ^a,c   Leboeuf, Nicole R ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acneiform; Breast cancer; Breast oncology; Cutaneous toxicities; Dermatologic adverse events; EGFR inhibitors

Indexed keywords

ANASTROZOLE; BENZOYL PEROXIDE; CARBOPLATIN; CLINDAMYCIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROCORTISONE; METRONIDAZOLE; MINOCYCLINE; NAVELBINE; PACLITAXEL; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ACNE; ADULT; ARTICLE; BREAST CARCINOMA; CASE REPORT; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LOADING DRUG DOSE; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PAPULAR RASH; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ACNEIFORM ERUPTIONS; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMICALLY INDUCED; DRUG ERUPTIONS; MIDDLE AGED; PATHOLOGY; TOPICAL DRUG ADMINISTRATION;

ACNEIFORM ERUPTIONS; ADMINISTRATION, TOPICAL; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BENZOYL PEROXIDE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINDAMYCIN; DRUG ERUPTIONS; FEMALE; HUMANS; MIDDLE AGED; MINOCYCLINE; RECEPTOR, ERBB-2;

EID: 84920461924     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.09.003     Document Type: Article

References (15)

1. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 3310
2. M.E. Lacouture, S.M. Laabs, and M. Koehler Analysis of dermatologic events in patients with cancer treated with lapatinib Breast Cancer Res Treat 114 2009 485 493
3. S. Segaert, and E. Van Cutsem Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann Oncol 16 2005 1425 1433
4. A.M. Drucker, S. Wu, C.T. Dang, and M.E. Lacouture Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis Breast Cancer Res Treat 135 2012 347 354
5. G. Jerusalem, A. Fasolo, and V. Dieras Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer Breast Cancer Res Treat 125 2011 447 455
6. S.L. Boone, A. Rademaker, D. Liu, C. Pfeiffer, D.J. Mauro, and M.E. Lacouture Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results Oncology 72 2007 152 159
7. F. Mascia, V. Mariani, G. Girolomoni, and S. Pastore Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation Am J Pathol 163 2003 303 312
8. I.Y. De Potter, Y. Poumay, K.A. Squillace, and M.R. Pittelkow Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation Exp Cell Res 271 2001 315 328
9. M.M. Marques, N. Martinez, I. Rodriguez-Garcia, and A. Alonso EGFR family-mediated signal transduction in the human keratinocyte cell line HaCaT Exp Cell Res 252 1999 432 438
10. L.B. Saltz, N.J. Meropol, P.J. Loehrer Sr, M.N. Needle, J. Kopit, and R.J. Mayer Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208
11. J.R. Hecht, A. Patnaik, and J. Berlin Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer Cancer 110 2007 980 988
12. B. Vincenzi, D. Santini, and C. Rabitti Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial Br J Cancer 94 2006 792 797
13. M.E. Lacouture, E.P. Mitchell, and B. Piperdi Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer J Clin Oncol 28 2010 1351 1357
14. R. Perez-Soler, and L. Saltz Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23 2005 5235 5246
15. M.E. Lacouture, M.J. Anadkat, and R.J. Bensadoun Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities Support Care Cancer 19 2011 1079 1095